EL
Eli Lilly
Indianapolis, Indiana, United StatesFounded 2001
Eli Lilly's venture capital arm, Lilly Ventures, strategically invests in early to expansion-stage life science and healthcare companies, focusing on emerging science in areas like immunology, oncology, cardio-metabolic, and neuroscience. Additionally, Eli Lilly manages a Social Impact Venture Capital Portfolio, which makes for-profit investments to address racial injustice and improve access to quality healthcare for marginalized communities and in limited-resource settings globally.
50% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Average disclosed round size is $70.2M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$800M
Top Stage
Growth
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Strand Therapeutics | Growth | $153M | Aug 2025 |
| BBasys.ai | Pre-Seed | $2.4M | Aug 2023 |
| IIterative Scopes | Series A | $30M | Aug 2021 |
 Evox Therapeutics | Series C | $95.4M | Feb 2021 |
Top Co-Investors
Kinnevik1 shared
Iconiq Capital1 shared
Playground Global1 shared
Obvious Ventures1 shared
Johnson & Johnson Innovation1 shared
Breyer Capital1 shared
Time BioVentures1 shared
Redmile Group1 shared
OrbiMed1 shared
Invus1 shared
Oxford Sciences Innovation1 shared
GV (Google Ventures)1 shared
Cowen Healthcare Investments1 shared
Mayo Clinic1 shared
Two Lanterns1 shared
Last updated: 12 April 2026